Comparative Pharmacology
Head-to-head clinical analysis: PERMITIL versus PERSERIS KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PERMITIL versus PERSERIS KIT.
PERMITIL vs PERSERIS KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antagonist at dopamine D2 receptors, also blocks alpha-1 adrenergic, histaminergic, and muscarinic receptors.
Risperidone, the active component of PERSERIS, is an atypical antipsychotic with antagonist activity at dopamine D2 and serotonin 5-HT2A receptors. It also binds to α1-adrenergic, α2-adrenergic, and histamine H1 receptors.
2.5-10 mg orally every 8-12 hours; maximum 40 mg/day. For severe psychosis: initial 10 mg IM, then 5-10 mg IM every 6-8 hours; maximum 30 mg/day IM.
Subcutaneous injection: 90 mg every 28 days for maintenance treatment of schizophrenia.
None Documented
None Documented
Terminal elimination half-life: 20-30 hours; clinically, steady-state achieved in 5-7 days; prolonged in elderly and hepatic impairment
Terminal elimination half-life is approximately 15 days (range 10-20 days) for the extended-release injectable formulation, reflecting slow release from the depot and sustained plasma concentrations.
Renal: <1% unchanged; Hepatic: extensively metabolized, metabolites excreted in urine (50-60%) and feces (30-40%)
Primarily hepatic metabolism via CYP2D6 and CYP3A4; approximately 30-40% of a dose is excreted in urine as metabolites, with less than 1% as unchanged drug. Biliary/fecal elimination accounts for about 60-70%.
Category C
Category C
Antipsychotic
Antipsychotic